Discuss the mechanism through which the NLEM influences drug pricing in India. What reforms are needed to ensure timely revision of the list?

Q. Discuss the mechanism through which the NLEM influences drug pricing in India. What reforms are needed to ensure timely revision of the list? (15 marks, 250-350 words)

The National List of Essential Medicines (NLEM), notified by the Ministry of Health and Family Welfare, identifies medicines meeting priority healthcare needs. Its real power is economic: inclusion in the NLEM triggers statutory price control, making the list India's single biggest lever on medicine affordability — but only if revised on time.

Mechanism of price influence - Listing to Schedule-I: NLEM medicines issued by MoHFW are incorporated into Schedule-I of the Drugs (Prices Control) Order, 2013, converting them into "scheduled formulations" [1]. - Ceiling price fixation by NPPA: the National Pharmaceutical Pricing Authority fixes ceiling prices for scheduled formulations; manufacturers and importers must sell within that price plus local taxes [2]. - Annual indexation: ceiling prices are revised each year by the Wholesale Price Index, notified on 1 April, balancing affordability with industry viability [2]. - Measurable outcome: price fixation under NLEM 2022 produced an average 17% price reduction and estimated annual savings of ₹3,788 crore to patients [3]. - Non-price effects: listed drugs guide free dispensation in government hospitals and public procurement, extending access beyond pricing.

Reforms for timely revision - Fixed revision cycle: mandate a statutory biennial review, mirroring WHO's two-year cycle; India's list of 384 medicines remains unrevised since 2022 while WHO issued its 24th Model List (2025) adding cancer and diabetes therapies [4][5]. - Permanent, resourced secretariat: give the Standing National Committee on Medicines continuous staffing and health-technology-assessment capacity instead of ad hoc reconstitution. - Institutional coordination: a standing MoHFW–NPPA–Department of Pharmaceuticals mechanism to compress the lag between listing and ceiling-price notification. - Transparency: publish review timelines, evidence dossiers and stakeholder comments to invite public scrutiny.

The NLEM works only as fast as it is updated; a stale list silently excludes newer therapies from price control. Institutionalising a predictable, evidence-driven revision calendar would align India with WHO practice and advance the right to affordable healthcare under Article 21 and SDG-3's universal health coverage goal.

(~330 words)

Sources: 1. Drugs (Prices Control) Order, 2013 — NPPA — NLEM incorporation into Schedule-I; scheduled formulations 2. PIB: Prices of drugs regulated under DPCO, 2013 (NPPA ceiling prices, WPI revision) — ceiling price fixation, compliance obligation, annual WPI indexation 3. PIB: Average price reduction under NLEM 2022 — annual savings of ₹3,788 crore — 17% average reduction; ₹3,788 crore savings 4. NLEM 2022 — NPPA — 384 medicines; list last revised 2022 5. WHO updates list of essential medicines to include key cancer, diabetes treatments (5 Sept 2025) — 24th WHO Model List; biennial revision; new cancer/diabetes additions